Thanks for the response. Speaking generally, it seems to me that it’s common sense that companies are protected to some degree when repurposing established drugs, otherwise there would be a great disincentive to do so. I’m a very recent buyer and am excited about the future. Particularly, as I myself may one day benefit from this amazing drug!
Thanks for the response. Speaking generally, it seems to me that...
-
- There are more pages in this discussion • 87 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
23.0¢ |
Change
0.005(2.22%) |
Mkt cap ! $81.36M | |||
| Open | High | Low | Value | Volume |
| 22.5¢ | 24.0¢ | 22.5¢ | $132.4K | 570.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 26000 | 23.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.5¢ | 63529 | 6 |
View Market Depth
| Last trade - 14.10pm 13/11/2024 (20 minute delay) ? |
| PAR (ASX) Chart |